MAD2L2 and glioblastoma: Using UALCAN [40], we analyzed the expression of MAD2L2 in pan-cancer, including glioblastoma (GBM), and found that the transcription levels of MAD2L2 were significantly elevated in almost all cancer tissues compared to normal or adjacent tissues.